Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus H CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus H CORT.
CORTONE vs H-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Category C
Category C
Corticosteroid
Corticosteroid